BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21224087)

  • 1. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen.
    Troyer JK; Feng Q; Beckett ML; Wright GL
    Urol Oncol; 1995; 1(1):29-37. PubMed ID: 21224087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen.
    Smith-Jones PM; Vallabahajosula S; Goldsmith SJ; Navarro V; Hunter CJ; Bastidas D; Bander NH
    Cancer Res; 2000 Sep; 60(18):5237-43. PubMed ID: 11016653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells.
    Barren RJ; Holmes EH; Boynton AL; Misrock SL; Murphy GP
    Prostate; 1997 Jan; 30(1):65-8. PubMed ID: 9018338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line.
    Troyer JK; Beckett ML; Wright GL
    Prostate; 1997 Mar; 30(4):232-42. PubMed ID: 9111600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
    Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of prostate-specific membrane antigen in the serum with a new antibody.
    Murphy GP; Tino WT; Holmes EH; Boynton AL; Erickson SJ; Bowes VA; Barren RJ; Tjoa BA; Misrock SL; Ragde H; Kenny GM
    Prostate; 1996 Apr; 28(4):266-71. PubMed ID: 8602402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
    Wright GL; Haley C; Beckett ML; Schellhammer PF
    Urol Oncol; 1995; 1(1):18-28. PubMed ID: 21224086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
    Murphy GP; Kenny GM; Ragde H; Wolfert RL; Boynton AL; Holmes EH; Misrock SL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Gilbaugh J
    Urology; 1998 May; 51(5A Suppl):89-97. PubMed ID: 9610563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
    Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
    Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
    Horoszewicz JS; Kawinski E; Murphy GP
    Anticancer Res; 1987; 7(5B):927-35. PubMed ID: 2449118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PSMA specific antibodies and their diagnostic and therapeutic use.
    Holmes EH
    Expert Opin Investig Drugs; 2001 Mar; 10(3):511-9. PubMed ID: 11227049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
    Chang SS; Reuter VE; Heston WD; Gaudin PB
    Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids.
    Troyer JK; Beckett ML; Wright GL
    Int J Cancer; 1995 Sep; 62(5):552-8. PubMed ID: 7665226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector.
    Kuratsukuri K; Wang CY; Sone T; Nishisaka N; Jones RF; Haas GP
    Eur Urol; 2002 Jul; 42(1):67-73. PubMed ID: 12121733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium.
    Liu H; Moy P; Kim S; Xia Y; Rajasekaran A; Navarro V; Knudsen B; Bander NH
    Cancer Res; 1997 Sep; 57(17):3629-34. PubMed ID: 9288760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.